Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Arlington Research Center

Neither a doctor nor a teaching hospital

Research payments

$3,734,787

776 payments

Through program year 2025, Arlington Research Center is reported as receiving $3,734,787 in research payments, across 776 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $710,462 145
2024 Research $1,083,018 148
2023 Research $434,333 170
2022 Research $625,947 123
2021 Research $364,159 46
2020 Research $236,675 69
2019 Research $280,193 75

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $1,169,212 138 payments
  2. Incyte Corporation $580,097 355 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $481,747 39 payments
  4. Ucb SA $457,438 21 payments
  5. Pfizer Inc. $412,314 112 payments
  6. Sanofi US Services Inc. $119,715 3 payments
  7. Arcutis Biotherapeutics, Inc. $108,348 44 payments
  8. E.R. Squibb & Sons, L.L.C. $91,394 9 payments
  9. Almirall LLC $85,631 6 payments
  10. Aclaris Therapeutics, Inc. $62,885 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $444,370 29 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $370,974 8 payments
  3. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $298,579 25 payments
  4. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $216,109 17 payments
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis $140,828 130 payments
  6. Jak1 Dupilumab Comparator Study $130,587 22 payments
  7. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf $117,238 21 payments
  8. TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $113,097 5 payments
  9. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $109,208 2 payments
  10. A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo $100,429 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record